




Rivastigmine Transdermal Patch  
Lisidiming Toupitieji

S -N- -N- -3-[1-( ) ]-



C<sub>14</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>

250.34

[(2- ) , ]  
/ /

4.6mg/24

1 4.6mg/24

2 9.5mg/24



---

- 50kg

-

|           |          |     |           |           |             |   |
|-----------|----------|-----|-----------|-----------|-------------|---|
|           |          |     | 4.6mg/24  | 9.5mg/24  | 13.3mg/24   |   |
| 17.4mg/24 |          |     |           | 13.3mg/24 | 17.4mg/24   |   |
|           |          |     |           |           |             | 1 |
|           | 9.5mg/24 |     |           |           |             |   |
| /         |          |     |           |           |             | / |
|           |          |     | 17.4mg/24 | *         |             |   |
|           |          |     |           | 9.5mg/24  |             |   |
| 2         |          |     |           |           |             |   |
|           |          | 1 2 |           |           |             |   |
| ( 10%)    | (1%~10%  | 1%) | (0.1%~1%  | 0.1%)     | (0.01%~0.1% |   |
| 0.01%)    | (<0.01%) |     |           |           |             |   |
| <b>1</b>  |          |     |           |           |             |   |

|  |
|--|
|  |
|  |
|  |
|  |

\* 13.3mg/24

\* 17.4mg/24

\*\* 24 " "

\*\*\* 24 " "

/

|  |        |         |         |        |         |
|--|--------|---------|---------|--------|---------|
|  | 18 6.2 | 57 18.8 | 50 17.0 | 10 3.3 | 75 12.6 |
|  | 18 6.2 | 31 10.2 | 16 5.4  | 10 3.3 | 49 8.2  |
|  | 8 2.7  | 23 7.6  | 16 5.4  | 4 1.3  | 31 5.2  |
|  | 7 2.4  | 21 6.9  | 22 7.5  | 7 2.3  | 28 4.7  |
|  | 2 0.7  | 15 5.0  | 12 4.1  | 3 1.0  | 17 2.9  |
|  | 10 3.4 | 13 4.3  | 18 6.1  |        |         |

2.2%

3.7%

-

- /
- 

---

---

3

4.6mg/24

/

---

/

---

QT /



•

\_\_\_\_\_

/

/

\_\_\_\_\_

\_\_\_\_\_

/

\_\_\_\_\_

/

/

/

\_\_\_\_\_

88% 65

55% 75

/

P450

\_\_\_\_\_

\_\_\_\_\_

/

\_\_\_\_\_

/

/

/

\_\_\_\_\_

/

\_\_\_\_\_

\_\_\_\_\_

-

/

-

\_\_\_\_\_

\_\_\_\_\_

n=75

549

12mg/

/

/

23%

\_\_\_\_\_

/

/

/

/

/

24

48

24

10-20

24

ADAS-Cog  
ADCS-CGIC

ADCS-ADL

3

24

4

4

3

24

| ITT-LOCF                   | 9.5mg/24<br>N=251                                     | 12mg/<br>N=256  | N=282                          |
|----------------------------|---|---|--------------------------------|
| ADAS-Cog<br>±<br>24 ±<br>p | n=248<br>27.0±10.3<br>-0.6±6.4<br>0.005* <sup>1</sup> | n=253<br>27.9±9.4<br>-0.6±6.2<br>0.003* <sup>1</sup>  | n=281<br>28.6±9.9<br>1.0±6.8   |
| ADCS-CGIC<br>±<br>p        | n=248<br>3.9±1.20<br>0.010* <sup>2</sup>              | n=253<br>3.9±1.25<br>0.009* <sup>2</sup>              | n=278<br>4.2±1.26              |
| ADCS-ADL<br>±<br>24 ±<br>p | n=247<br>50.1±16.3<br>-0.1±9.1<br>0.013* <sup>1</sup> | n=254<br>49.3±15.8<br>-0.5±9.5<br>0.039* <sup>1</sup> | n=281<br>49.2±16.0<br>-2.3±9.4 |

\* p 0.05  
ITT  
1 LOCF

ADAS-Cog

ADCS-ADL

2 CMH van Elteren ADCS-CGIC <4

24

5

ADAS-Cog

4

ADCS-CGIC

ADCS-ADL

|                                    |          |                    |       |
|------------------------------------|----------|--------------------|-------|
|                                    | %        |                    |       |
|                                    | 9.5mg/24 | 12mg/ <sup>®</sup> |       |
| ITT-LOCF                           | N=242    | N=248              | N=276 |
| ADAS-Cog<br>4 ADCS-CGI<br>ADCS-ADL | 17.4     | 19.0               | 10.5  |
| p                                  | 0.037*   | 0.004*             |       |

\* p<0.05

9.5mg/24

12mg/

9.5mg/24

48

MMSE      10-24      24-48

9.5mg/24      13.3mg/24

9.5mg/24      48

2      3      MMSE

-      -      ADAS-Cog

-      -      ADACS-IADL

2      48      6

**6      ADAS-Cog      ADACS-IADL**


|  |                         |                        |                                  |
|--|-------------------------|------------------------|----------------------------------|
|  | (13.3mg/24h)<br>N = 265 | (9.5mg/24h)<br>N = 271 | -<br>(13.3mg/24h)<br>(9.5mg/24h) |
|  | DLSM                    |                        | 95% CI      P                    |

|  |                         |                        |   |                             |
|--|-------------------------|------------------------|---|-----------------------------|
|  | (13.3mg/24h)<br>N = 265 | (9.5mg/24h)<br>N = 271 | - | (13.3mg/24h)<br>(9.5mg/24h) |
|--|-------------------------|------------------------|---|-----------------------------|


-48



1 24



2



74% 103% 43% C<sub>max</sub> 49% AUC<sub>0-24h</sub>

71% 73% 45% C<sub>max</sub> 43% AUC<sub>0-24h</sub>

NAP-226-90

65kg  
100kg

35kg

2

|                 |      |                 |           |     |   |     |       |
|-----------------|------|-----------------|-----------|-----|---|-----|-------|
|                 |      |                 | $C_{max}$ | 60% | / | AUC | 2     |
| 3mg             | 6mg  |                 | /         |     |   |     |       |
| n=7, Child-Pugh | 5-6  | n=3, Child-Pugh | 7-9       |     |   |     | n=10, |
|                 | n=10 | 60-65%          |           |     |   |     |       |

---

7 / 30 /

36

JX20200001

Luye Pharma AG

Am Windfeld 35, 83714 Miesbach, Germany

Luye Pharma AG

Am Windfeld 35, 83714 Miesbach, Germany

15

15

264670

0535-6717618

0535-6717718

[www.luye.cn](http://www.luye.cn)

?

<

<

< 1

<

<

<

<

<

< 24

<

14

<

<

<

2

<

3

<

<

1

1

?

A

<

<

<

<

A







6

---

<

<

<

<

---